Ask AI
ProCE Banner Activity

Pirtobrutinib as 2L Therapy for CLL/SLL Following  cBTKi Therapy: Pooled Analysis of BRUIN LOXO-BTK18001 and BRUIN CLL-321

Conference Coverage
Slideset

A pooled analysis of the phase I/II BRUIN LOXO-BTK18001 and phase III BRUIN CLL-321 trials suggests that pirtobrutinib is safe and effective as second-line therapy in patients with CLL/SLL previously treated with a covalent BTK inhibitor with a median of nearly 3 years to next treatment.

Released: December 19, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals caring for patients with relapsed/refractory CLL globally.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with relapsed/refractory CLL

  • Appraise the potential clinical implications of new data on novel targeted and cellular therapies for treatment selection and sequencing in patients with relapsed/refractory CLL

  • Support effective shared decision-making through patient education and resources on the potential clinical implications of recently presented data for relapsed/refractory CLL